Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.
Zhen Zeng(Sun Yat-sen University), Jundong Li(University of Virginia), Zhihao Jiang(Sun Yat-sen University), Lan-Yue Cui(Sun Yat-sen University), Wei Wei(Zhujiang Hospital)
Cited by 0
Related Papers
Feature Selection
|ACM Computing Surveys|2017|2.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Line Graph Neural Networks for Link Prediction
|IEEE Transactions on Pattern Analysis and Machine Intelligence|2021|235
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216